Biotech, in brief

AstraZeneca set out on Friday why its heart drug gave no extra benefit to people already on another medicine. [2]

The trial was called CARDIO-TTRansform. It enrolled more than 1,400 people and ran for 140 weeks. [1]

29% of those on the drug had a heart event or died. On dummy injections it was 32%. [1]

That gap was too small to count as a real effect, so the trial missed its main goal. [1]

The disease is ATTR-CM. A blood protein called transthyretin folds wrong and stiffens the heart muscle. [1]

Two kinds of drug already exist for it. Stabilisers hold the protein in its correct shape. [1]

Silencers, including this one, stop the body making the faulty protein. Both aim at the same protein. [1]

81% of this trial's volunteers were already on a stabiliser. In the rival trial that succeeded, it was 53%. [1]

The investigators told the New England Journal of Medicine that stabiliser use kept rising while the study ran. [1]

Jefferies analyst Michael Leuchten wrote that adding a silencer on top may simply help less than everyone assumed. [1]

Analysts said the result strengthens the case that swallowed stabilisers may beat injected silencers. [2]

Alnylam sells a silencer of its own. Its shares are down about 30% since the failure was announced in July. [1]

That one drug earned Alnylam $1.9bn in the first half of 2026, which is 86% of the company's revenue. [1]

Stifel's Paul Matteis wrote it is now hard to see a path to approval for eplontersen in this disease. [1]

A Cedars-Sinai heart specialist, Michelle Kittleson, wrote up for NEJM what the negative result changes in the clinic. [3]

Why it matters. Watch who Alnylam lets into its next-generation trial. One analyst has already suggested enrolling fewer treated patients, which would raise its odds and concede the point this failure just made. [1]

Fifteen patients got a single gene-editing treatment for high cholesterol. Those on the highest dose saw levels fall by half, and they were still down a year later. [4]

Why it matters. Gene editing has been for rare fatal diseases. This one goes at a common condition that daily pills already treat, and about half the people who start those pills stop. [4]

The state's outbreak grew to 460 cases by Friday. [6] Two unvaccinated residents of Lancaster County died last week. [8] They were the first US measles deaths of 2026 and the state's first in 35 years. [39]

Why it matters. Before the vaccine arrived in 1963 the US had 3 to 4 million cases a year and 400 to 500 deaths. [39]

Robert F. Kennedy Jr.'s comments on vaccines drew criticism while the outbreak was still growing. [7] Pennsylvania's governor Josh Shapiro had called the deaths completely preventable and named the MMR shot as the best protection. [40]

Why it matters. In Lancaster County, where the deaths happened, 85% of kindergarten-age children have the shot, below the 95% the state says it needs. [40]

The FDA approved rusfertide, sold as Mimrylo, for polycythemia vera, a slow blood cancer affecting about 90,000 Americans. Patients have historically relied on frequent bloodletting. Takeda projects $1bn to $2bn in peak sales. [5]

Why it matters. It is the rare case where the new treatment replaces a procedure rather than another drug.

Roivant and Priovant set a list price of $35,000 for a 30-day supply of Lisraya. It was approved the day before for dermatomyositis, a disease of painful skin rashes and weakening muscles. [36]

Why it matters. It is the first targeted pill for the condition, and the price arrived one day after the approval.

Moderna priced an enlarged convertible note offering at $2.6bn, having proposed $2bn a week earlier. It follows the phase 3 success of its cancer vaccine with Merck. [9][37]

Why it matters. The company added $45bn in market value the day those results landed, then borrowed against the mood. [9]

The FDA approved Gilead's Bixlenvo, one tablet combining bictegravir and lenacapavir, for people whose HIV is already suppressed, including those on complicated drug schedules. [9]

Why it matters. Fewer pills is often the difference between a treatment that works and one a person keeps up with.

Generate Biomedicines' shares fell by double digits after three embargoed posters on its asthma and lung drug golukibart were made public before a European conference. [9]

Why it matters. The findings had not changed. Only the order in which people saw them had.

ProFound Therapeutics secured a $35m commitment from the Gates Foundation, starting with $20m, to hunt for drug targets in preeclampsia and eclampsia using artificial intelligence. [9]

Why it matters. Both conditions are described by the foundation's own AI chief as underdiagnosed and undertreated. [9]

The Gates Foundation pledged $540m over ten years to the Institute for Health Metrics and Evaluation, the largest grant in the University of Washington's history. [10]

Why it matters. It publishes the Global Burden of Disease study, which covers 375 diseases across 204 countries and guides where health money goes. [10]

Researchers say the institute's models are opaque and lean on data skewed to rich countries. A 2015 edition named cholera the leading cause of diarrhoea deaths in Canada, and was corrected without explanation. [10]

Why it matters. The same numbers steer national health spending, so a modelling error is not an academic one.

Twenty drug developers have listed in 2026, against 11 in all of last year, with fourteen raising over $250m each. Bankers counted 80 acquisitions worth $96bn upfront in the first half. [12]

Why it matters. Buyers are picking approved or late-stage drugs, because $200bn of big-pharma revenue loses patent protection by 2030. [12]

A Massachusetts industry report found seed rounds shrinking while later rounds grow. The group named the earliest startups with the riskiest science as its biggest concern. Employment fell 3% year on year. [13][14]

Why it matters. The recovery is real and it is landing on companies that already had money.

Licensing deals for drugs discovered in China totalled $79bn last year, against about $1bn in 2019. China now runs more early-stage trials than any other place the report measured. [13]

Why it matters. A US startup now competes for the same buyer against a finished Chinese asset.

Venture money into women's health companies dropped from $3.2bn in 2024 to about $2bn in 2025. Among drug startups specifically it fell from $1.3bn to $610m. [15]

Why it matters. Investors moved to safer, later-stage bets, and the newest areas lost most.

Arch Venture Partners and Population Health Partners incorporated Sentivera twelve days after Pfizer closed its $10bn purchase of their last startup. [16] It has licensed a Chinese inflammation drug for up to $1.5bn. [16][17]

Why it matters. The upfront cash was $40m. The rest depends on a drug only just cleared to enter human testing in China. [16]

BioXcel Therapeutics filed for bankruptcy after telling investors it could not fund operations past August. Teva was named the lead bidder, able to take substantially all its assets for $57.5m upfront. [11]

Why it matters. In the same week the sector index sat near a record high.

A real-world study followed adults over 55. Those who stayed on Eli Lilly's Zepbound had monthly costs $181 lower at six months and $607 lower at a year. Most of the saving came from fewer hospital and emergency visits. [17]

Why it matters. Lilly funded and announced it, and the saving depends entirely on people staying on the drug. [17]

Monitors stopped a phase 3 trial early after Akeso's ivonescimab plus chemotherapy improved survival against an immunotherapy-chemotherapy combination in first-line biliary tract cancer. Summit's shares rose 14%. [17]

Why it matters. Akeso says it is the first time any therapy has beaten that combination in this cancer. No figures were released. [17]

A tool called prime assembly cut out stretches of genome up to a million letters long. It then dropped in donor DNA of one to six thousand letters. Inserting a 2.9-thousand-letter donor worked in up to 57.8% of cultured cells. [18]

Why it matters. Editing has mostly changed single letters. Replacing a whole gene is a different scale of repair.

About half of patients relapse after CD19 CAR-T therapy. Researchers found the two approved products differ: repeated exposure to one design drove tumour cells to lose the CD19 target, while the other did not. [19]

Why it matters. The escape route was written into the engineering, not into the cancer.

Among 104 CAR-T recipients, having CHIP overall predicted nothing. But patients whose pre-existing clones carried TP53 mutations had lower platelets and haemoglobin and worse outcomes. [20]

Why it matters. The useful signal was invisible until the group was split by which mutation it carried.

Boston University researchers found that switching off Notch signalling late in development, while damping another signal, let stem cells mature into CD4 helper T cells at scale. [21]

Why it matters. CAR-T is built from each patient's own cells, which is why it is so expensive. Off-the-shelf cells are the way out.

Old mice accumulate killer CD4 T cells in the marrow that skew blood production. Blocking their signal with maraviroc, an approved HIV drug, normalised the effect and improved several ageing measures. [22]

Why it matters. It worked in mice. Most things that work in mice never work in people.

In 31 patients with nasopharyngeal cancer that had already resisted platinum chemotherapy and immunotherapy, an antibody-drug pairing shrank tumours in 71%, with responses lasting a median 14 months. [23]

Why it matters. Four in ten had a serious side effect, and 31 patients is a small early trial. [23]

Twenty-four patients got two immune drugs before their colon cancer operation. In the harder-to-treat group, 41% had a major reduction in tumour tissue by the time of surgery, and no surgery was delayed. [24]

Why it matters. Immunotherapy has mostly failed in this form of colon cancer.

Researchers benchmarked five structure-prediction models against experimental structures published after each model's training cut-off. AlphaFold-based models did best overall, but accuracy dropped sharply on the largest enzyme. [25]

Why it matters. Testing only on structures released after the training date is what stops a model scoring on answers it has already seen.

Machine-learning models trained on 255 mass readings told viruses from bacteria and named individual species. They then held up against an outside database of dangerous bacteria held by the Robert Koch Institute. [26]

Why it matters. Speed of identification is what decides which antibiotic a patient gets on day one.

A pipeline pairing a construct-screening program with a designed marker protein solved structures of receptors that had resisted the usual trial and error, including one bound to the drug tolvaptan. [27]

Why it matters. This receptor family is behind a large share of all drugs, and its resting shape has been the hard one to see.

A framework called MAP joined 14 public databases into one map of 187,089 drugs, 22,924 genes and 694,246 relationships. It then predicted how cells react to compounds it had never seen, beating the best existing models by about 12%. [28]

Why it matters. Only a sliver of possible compounds has ever been tested in cells.

A paper in Nature Biomedical Engineering looks at the low odds of a drug surviving from first human test to approval. The authors argue the shortage is not of data. It is of turning data into decisions about what to stop. [29]

Why it matters. It proposes running development as a loop that updates, rather than a pipeline that proceeds.

Marc Powell, 60, has the SOD1 form of motor neurone disease, which affects fewer than 100 people in the UK. Biogen supplies tofersen free to some centres, but hospitals must fund giving it, so places are few. [30]

Why it matters. The NHS has not commissioned the drug. The barrier is the cost of administering a free medicine. [30]

Spruce Biosciences said two FDA meetings supported its plan to file in the fourth quarter for an enzyme replacement therapy for Sanfilippo syndrome type B. The filing had slipped from the first quarter over manufacturing data. [31]

Why it matters. Analysts had called the clinical data solid and the manufacturing risk hard to quantify. [31]

Saudi officials writing on their national biotech strategy argue a country can sequence its whole population and still treat nobody. Gene therapies and engineered cells have to be made to sterile standards, at scale. [32]

Why it matters. It is the same constraint that put a US cell-therapy factory maker into layoffs this week.

Doctors writing in Nature Medicine say May's Ebola emergency sits inside a wider collapse in eastern Congo. More than 7 million people there are displaced, and humanitarian funding has been cut. [33]

Why it matters. Surveillance and medicine buying were among the first functions to stop, which affects malaria, TB and HIV. [33]

The NIH asked for public comment on a draft policy making it standard practice to share summary study results with the people who took part in the research. [34]

Why it matters. Trial volunteers currently have no general right to be told what their own study concluded.

A Nature Reviews Cancer roadmap says bowel cancer under 50 is rising worldwide. Obesity, diet and inactivity are linked to it. When and how those risks act is still unknown. [35]

Why it matters. Prevention advice cannot be written until someone knows which exposure matters and at what age.

Shares in several DNA sequencing companies climbed alongside Moderna and Merck after what the two companies called the first positive phase 3 result for a personalised cancer vaccine. [38]

Why it matters. Each dose is built from that patient's own tumour, so the vaccine cannot exist without sequencing. [38]